Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy.

[1]  Hongwu Tan,et al.  A tumour‐promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways , 2017, Clinical and experimental pharmacology & physiology.

[2]  Yong-ming Yao,et al.  Interleukin-37 Enhances the Suppressive Activity of Naturally Occurring CD4+CD25+ Regulatory T Cells , 2016, Scientific Reports.

[3]  M. Pellegrini,et al.  The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde , 2016, Clinical & translational immunology.

[4]  Xu-dong Liu,et al.  Interleukin-21 Is Associated with Early Antiviral Response in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. , 2016, Journal of Interferon and Cytokine Research.

[5]  S. Alavian,et al.  Manipulation of Regulatory Cells’ Responses to Treatments for Chronic Hepatitis B Virus Infection , 2016, Hepatitis monthly.

[6]  Yan-fang Jiang,et al.  Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. , 2016, World journal of gastroenterology.

[7]  S. Tavakolpour The new insight into management of hepatitis B virus patients with flare. , 2016, Immunology letters.

[8]  S. Tavakolpour Interleukin 21 as a new possible player in pemphigus: Is it a suitable target? , 2016, International immunopharmacology.

[9]  S. Alavian,et al.  Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review , 2016, Hepatitis monthly.

[10]  R. Ueda,et al.  Current status of immunotherapy. , 2016, Japanese journal of clinical oncology.

[11]  S. Tavakolpour Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients. , 2016, Immunology letters.

[12]  S. Tavakolpour Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases , 2016 .

[13]  H. Fujii,et al.  Interleukin-17A Plays a Pivotal Role in Chemically Induced Hepatocellular Carcinoma in Mice , 2016, Digestive Diseases and Sciences.

[14]  Y. Xiang,et al.  The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis , 2015, PloS one.

[15]  Cheng-song Sun,et al.  Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy , 2015, Acta Pharmacologica Sinica.

[16]  Lemonica Koumbi Current and future antiviral drug therapies of hepatitis B chronic infection. , 2015, World journal of hepatology.

[17]  Wenhong Zhang,et al.  Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment , 2015, Antimicrobial Agents and Chemotherapy.

[18]  Wang-xian Tang,et al.  Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses , 2015, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[19]  X. Liu,et al.  T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance , 2015, Cell Death and Disease.

[20]  S. Manzoor,et al.  IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma , 2015, Tumor Biology.

[21]  V. Wong,et al.  Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B , 2014, Journal of viral hepatitis.

[22]  M. Ota,et al.  Serum levels of interleukin‐22 and hepatitis B core‐related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  S. Kottilil,et al.  Strategies to eliminate HBV infection. , 2014, Future virology.

[24]  Jinhong Chang,et al.  Therapeutic strategies for a functional cure of chronic hepatitis B virus infection , 2014, Acta pharmaceutica Sinica. B.

[25]  M. El-Houseini,et al.  Potential immunotherapeutic role of interleukin-2 and interleukin-12 combination in patients with hepatocellular carcinoma , 2014, Journal of hepatocellular carcinoma.

[26]  Jun Yu,et al.  Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. , 2014, World journal of gastroenterology.

[27]  G. Xiao,et al.  Prevalence and Clinical Relevance of T-Helper Cells, Th17 and Th1, in Hepatitis B Virus-Related Hepatocellular Carcinoma , 2014, PloS one.

[28]  K. Chayama,et al.  Serum interleukin‐6 associated with hepatocellular carcinoma risk: A nested case–control study , 2014, International journal of cancer.

[29]  M. Arababadi,et al.  Current information concerning association of IL-12 and hepatitis B infection. , 2014, Clinical Laboratory.

[30]  A. Busca,et al.  Innate immune responses in hepatitis B virus (HBV) infection , 2014, Virology Journal.

[31]  Han‐Chieh Lin,et al.  Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments , 2013, International journal of cancer.

[32]  M. Zheng,et al.  Emerging Role of Interleukin 22 in Hepatitis B Virus Infection: a Double-edged Sword , 2013, Journal of clinical and translational hepatology.

[33]  A. Bertoletti,et al.  Immune Therapeutic Strategies in Chronic Hepatitis B Virus Infection: Virus or Inflammation Control? , 2013, PLoS pathogens.

[34]  S. Sarin,et al.  Immunological mechanisms of hepatitis B virus persistence in newborns , 2013, The Indian journal of medical research.

[35]  J. Lian,et al.  Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B. , 2013, Viral immunology.

[36]  Yanfang Jiang,et al.  Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[37]  Li-na Ma,et al.  Extended treatment with peginterferon α‐2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion , 2013, Journal of digestive diseases.

[38]  Jing Zhao,et al.  IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. , 2013, Antiviral research.

[39]  J. Luk,et al.  Interleukin 23 Promotes Hepatocellular Carcinoma Metastasis via NF-Kappa B Induced Matrix Metalloproteinase 9 Expression , 2012, PloS one.

[40]  B. Ni,et al.  Effects of Telbivudine Treatment on the Circulating CD4+ T-Cell Subpopulations in Chronic Hepatitis B Patients , 2012, Mediators of inflammation.

[41]  Zhi‐hua Liu,et al.  High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. , 2012, Journal of hepatology.

[42]  Y. Li,et al.  Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. , 2012, Viral immunology.

[43]  H. Ren,et al.  Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients , 2012, Clinical and Experimental Medicine.

[44]  Younhee Park,et al.  Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy , 2011, Journal of clinical laboratory analysis.

[45]  D. Hedley,et al.  Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary Cells , 2011, Journal of acquired immune deficiency syndromes.

[46]  Lanjuan Li,et al.  Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. , 2011, Antiviral research.

[47]  D. Long,et al.  Increased Frequency of CD4+CD25highFoxP3+ Regulatory T Cells in Patients with Hepatocellular Carcinoma , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[48]  Y. Hiasa,et al.  Mechanism of restoration of immune responses of patients with chronic hepatitis B during lamivudine therapy: increased antigen processing and presentation by dendritic cells , 2011, Journal of viral hepatitis.

[49]  Steven‐Huy B. Han,et al.  Combination Therapy for Chronic Hepatitis B: Current Indications , 2011, Current hepatitis reports.

[50]  S. Sarin,et al.  Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate , 2011, Journal of Clinical Immunology.

[51]  J. Yeon,et al.  HBsAg Seroclearance in Chronic Hepatitis B: Implications for Hepatocellular Carcinoma , 2011, Journal of clinical gastroenterology.

[52]  J. Niu,et al.  Th1 and Th2 Immune Response in Chronic Hepatitis B Patients during a Long-Term Treatment with Adefovir Dipivoxil , 2010, Mediators of inflammation.

[53]  Jiyuan Zhang,et al.  Decreased Ratio of Treg Cells to Th17 Cells Correlates with HBV DNA Suppression in Chronic Hepatitis B Patients Undergoing Entecavir Treatment , 2010, PloS one.

[54]  H. Janssen,et al.  The Role of Interferon in Hepatitis B Therapy , 2010, Current hepatitis reports.

[55]  A. Lok,et al.  Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. , 2009, Journal of hepatology.

[56]  B. Becher,et al.  IL-9 as a mediator of Th17-driven inflammatory disease , 2009, The Journal of experimental medicine.

[57]  N. Terrault Benefits and risks of combination therapy for hepatitis B , 2009, Hepatology.

[58]  Mong-Liang Chen,et al.  HBV replication is significantly reduced by IL-6 , 2009, Journal of Biomedical Science.

[59]  N. Terrault Benefits and Risks of Combination Therapy for Hepatitis , 2009 .

[60]  S. Chokshi,et al.  Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e‐antigen seroconversion , 2008, Hepatology.

[61]  Dong-yun Zhang,et al.  Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection. , 2007, World journal of gastroenterology.

[62]  E. Kuipers,et al.  Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. , 2007, Virology.

[63]  R. Flavell,et al.  IL9 leads to airway inflammation by inducing IL13 expression in airway epithelial cells. , 2006, International immunology.

[64]  J. G. Kusters,et al.  Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV , 2006, Hepatology.

[65]  L. Ye,et al.  Pathogenesis of hepatitis B virus infection , 2006 .

[66]  P. Lipsky,et al.  TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.

[67]  Roger Williams,et al.  Lamivudine plus interleukin‐12 combination therapy in chronic hepatitis B: Antiviral and immunological activity , 2005, Hepatology.

[68]  G. Doria,et al.  IL-4 Modulation of CD4+CD25+ T Regulatory Cell-Mediated Suppression1 , 2005, The Journal of Immunology.

[69]  E. Kuipers,et al.  Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection , 2005, Hepatology.

[70]  C. Siu,et al.  HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects , 2004, Hepatology.

[71]  B. Nelson IL-2, Regulatory T Cells, and Tolerance , 2004, The Journal of Immunology.

[72]  M. Bajénoff,et al.  IL-4-mediated inhibition of IFN-gamma production by CD4+ T cells proceeds by several developmentally regulated mechanisms. , 2004, International immunology.

[73]  D. Cantrell,et al.  Sustained IL-12 Signaling Is Required for Th1 Development 1 , 2004, The Journal of Immunology.

[74]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[75]  Sue-Jane Lin,et al.  IL-4 Suppresses the Expression and the Replication of Hepatitis B Virus in the Hepatocellular Carcinoma Cell Line Hep3B 1 , 2003, The Journal of Immunology.

[76]  M. Biermer,et al.  Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-κB , 2003, Journal of Virology.

[77]  M. Biermer,et al.  Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. , 2003, Journal of virology.

[78]  V. Calvez,et al.  Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus–infected patients: Results from a randomized control trial , 2002, Hepatology.

[79]  F. Chisari,et al.  Interleukin-12 inhibits hepatitis B virus replication in transgenic mice , 1997, Journal of virology.

[80]  N. Horiike,et al.  Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis. , 1987, Gut.